- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01458730
Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
August 3, 2022 updated by: University of Aarhus
Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomide.
The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objective of the study is
- To investigate the efficacy and safety of a high-dose methotrexate-based induction polychemotherapy regimen combined with Rituximab and intraspinal DepoCyte followed by temozolomide maintenance treatment in newly diagnosed primary central nervous system lymphoma
- To assess the long term outcome concerning neurotoxicity
Study Type
Interventional
Enrollment (Actual)
66
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aarhus, Denmark, DK-8000
- Elisa Jacobsen Pulczynski
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pathologically verified primary central nervous system lymphoma No prior PCNSL treatment.
- Patients treated with steroids alone are eligible
- No signs of lymphoma outside the CNS
- ECOG performance status 0-4
- Age > 17 and < 76 years
- Written informed consent from the patient or guardian
Exclusion Criteria:
- Cardiac failure > 3
- Pregnancy or lactation. Women of childbearing potential are requested to use an effective method of contraception to avoid pregnancy for a period from entry to the study and at least 3 months after the last study medication
- Previous malignancy unless disease free for at least five years
- Active infection.
- Regarding tuberculosis, patients at risk should be tested for latent TB according local practice at each treating centre.
- Positive HIV status
- Organ transplantation
- Serious psychiatric illness
- Prior radiotherapy to the brain
- Concomitant anti-inflammatory medication that cannot be discontinued
- Creatinine clearance < 60 ml/minute calculated by Cockcroft and Gault formula
- Peripheral blood count with granulocytes <1.5 x 109L or platelets < 100 x 109L
- Serum bilirubin >1.5 times or ASAT and alkaline phosphatase >2 times upper limits of normal.
- Known anaphylaxis or IgE-mediated hypersensitivity to murine protein or any component of Rituximab excludes patients from Rituximab treatment, but not from the remaining part of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Overall survival
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
response rate
Time Frame: at completion of therapy
|
at completion of therapy
|
neurotoxicity
Time Frame: 1-10 years after completion of therapy
|
1-10 years after completion of therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
August 1, 2022
Study Registration Dates
First Submitted
September 15, 2011
First Submitted That Met QC Criteria
October 24, 2011
First Posted (Estimate)
October 25, 2011
Study Record Updates
Last Update Posted (Actual)
August 4, 2022
Last Update Submitted That Met QC Criteria
August 3, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EudraCT No 2006-004772-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Nervous System Lymphoma
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Central Nervous System Lymphoma | Central Nervous System B-Cell Non-Hodgkin Lymphoma | Recurrent Central Nervous System LymphomaUnited States
-
James RubensteinIncyte CorporationRecruitingPrimary Central Nervous System Lymphoma | CNS Lymphoma | Secondary Central Nervous System LymphomaUnited States
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingPrimary Central Nervous System Lymphoma | Refractory Central Nervous System Lymphoma | Relapsed Primary Central Nervous System LymphomaChina
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)United States
-
Dana-Farber Cancer InstituteRecruitingRefractory Central Nervous System Lymphoma | Central Nervous System Lymphoma | Recurrent Central Nervous System LymphomaUnited States
-
Second Affiliated Hospital, School of Medicine,...First People's Hospital of Hangzhou; First Affiliated Hospital of Zhejiang... and other collaboratorsRecruitingPrimary Central Nervous System Hodgkin LymphomaChina
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedLymphoma, Non-Hodgkin | Central Nervous System NeoplasmsNorway
-
Institut CurieNational Cancer Institute, FranceRecruitingLymphoma, Large B-Cell, Diffuse | Central Nervous System Neoplasms, PrimaryFrance
-
Ono Pharmaceutical Co. LtdRecruitingPrimary CNS Lymphoma | Refractory Primary Central Nervous System LymphomaUnited States
-
Vanderbilt-Ingram Cancer CenterBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Central Nervous System Lymphoma | Recurrent Central Nervous System LymphomaUnited States
Clinical Trials on Immunochemotherapy
-
Shanghai Zhongshan HospitalCompleted
-
Hoffmann-La RocheCompletedNon-Hodgkin's LymphomaColombia, Mexico
-
Jiang FengRecruiting
-
Fondazione Italiana Linfomi - ETSRecruiting
-
Henan Cancer HospitalRecruitingEsophageal Cancer | Surgery | Survival | Neoadjuvant TreatmentChina
-
IRCCS Policlinico S. MatteoCompleted
-
TheracosCompletedType 2 Diabetes MellitusUnited States, Canada, Czechia, Denmark, Korea, Republic of, Mexico, Netherlands, Poland, Russian Federation, Taiwan
-
Centre hospitalier de l'Université de Montréal...University of British Columbia; McGill University; University of Alberta; McMaster... and other collaboratorsRecruitingCarotid Stenosis | Carotid Artery Diseases | Stroke, AcuteCanada
-
Cancer Institute and Hospital, Chinese Academy...RecruitingNon-Small Cell Lung CancerChina
-
Hunan Province Tumor HospitalRecruitingNon-small Cell Lung CancerChina